{'fraction_non_alphanumeric': 0.02404809619238477, 'fraction_numerical': 0.01503006012024048, 'mean_word_length': 5.3630573248407645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Megadosage of 6-methylprednisolone in systemic vasculitis with renal involvement. A prospective study].

A prospective, open and uncontrolled study of effectiveness and side effects of intravenous 6-methylprednisolone megadoses was carried out in 20 patients with systemic vasculitis with rapidly progressive renal failure. The results showed a favorable response of renal function in 80% of patients and a control of pulmonary hemorrhage in the patients in which it was present. Oliguria and the need for hemodialysis during the acute phase of the disease significantly reduced the response to treatment. Extracapillary proliferation in more than 80% of glomeruli resulted in a lesser degree of recovery of renal function. Severe side effects developed in 2 patients (10%), but they could be exclusively attributed to the 6-methylprednisolone megadose in 1 (5%). It was concluded that 6-methylprednisolone megadoses may be an effective therapeutic alternative for the treatment of these patients.